Tech Company Financing Transactions
Ultromics Funding Round
Ultromics closed a $55 million Series C funding round on 7/31/2025. Backers included Allegis Capital, Lightrock and Blue Venture Funds.
Transaction Overview
Company Name
Announced On
7/31/2025
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series C
Investors
Allegis Capital (Lead Investor)
Lightrock (Lead Investor)
Proceeds Purpose
The company intends to use the funds to expand operations and its R&D efforts.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
4630 Kingsgate, Cascade Way, Oxford Business Park South
Oxford, OX4 2SU
UK
Oxford, OX4 2SU
UK
Phone
Website
Email Address
Overview
At Ultromics, we are committed to improving outcomes for patients with heart failure, which affects 64 million people worldwide.[1?] Through the development of? AI-based solutions we help diagnose specific phenotypes of heart failure, beginning with HFpEF, so that patients can receive life-saving treatments earlier. Ultromics brings the power of artificial intelligence into your echocardiography workflow using a state-of-the-art platform that supports early heart failure diagnosis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
John Russell
Chief Executive Officer
Ross Upton
Chief Medical Officer
Paul Leeson
Chief Operating Officer
Amir Hasan
VP - Bus. Development
Roger Owens
VP - Product Management
Gary Woodward
VP - Regulatory Affairs
Jaco Jacobs
Browse more venture capital transactions:
Prev: 7/31/2025: fal - features and labels venture capital transaction
Next: 7/31/2025: SixSense venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs